- Home
- MYNZ vs MBIO Comparison
MYNZ vs MBIO Comparison
Compare MYNZ & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- MBIO
- Stock Information
- Founded
- MYNZ 2021
- MBIO 2015
- Country
- MYNZ Germany
- MBIO United States
- Employees
- MYNZ N/A
- MBIO N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- MBIO Health Care
- Exchange
- MYNZ Nasdaq
- MBIO Nasdaq
- Market Cap
- MYNZ 11.2M
- MBIO 9.1M
- IPO Year
- MYNZ 2021
- MBIO N/A
- Fundamental
- Price
- MYNZ $3.78
- MBIO $0.17
- Analyst Decision
- MYNZ Hold
- MBIO Strong Buy
- Analyst Count
- MYNZ 2
- MBIO 1
- Target Price
- MYNZ N/A
- MBIO $2.00
- AVG Volume (30 Days)
- MYNZ 128.8K
- MBIO 607.5K
- Earning Date
- MYNZ 10-21-2024
- MBIO 11-08-2024
- Dividend Yield
- MYNZ N/A
- MBIO N/A
- EPS Growth
- MYNZ N/A
- MBIO N/A
- EPS
- MYNZ N/A
- MBIO N/A
- Revenue
- MYNZ $917,203.00
- MBIO N/A
- Revenue This Year
- MYNZ $36.69
- MBIO N/A
- Revenue Next Year
- MYNZ $91.67
- MBIO N/A
- P/E Ratio
- MYNZ N/A
- MBIO N/A
- Revenue Growth
- MYNZ 16.23
- MBIO N/A
- 52 Week Low
- MYNZ $0.18
- MBIO $0.13
- 52 Week High
- MYNZ $7.95
- MBIO $1.53
- Technical
- Relative Strength Index (RSI)
- MYNZ 53.35
- MBIO 32.12
- Support Level
- MYNZ $4.30
- MBIO $0.16
- Resistance Level
- MYNZ $7.95
- MBIO $0.21
- Average True Range (ATR)
- MYNZ 0.91
- MBIO 0.02
- MACD
- MYNZ -0.15
- MBIO -0.00
- Stochastic Oscillator
- MYNZ 46.33
- MBIO 18.17
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.